Skip to content

Prognostic Significance of Fatty Liver Disease in Bariatric Patients

Prognostic Significance of Fatty Liver Disease in Bariatric Patients

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03535142
Acronym
PROMETHEUS
Enrollment
1200
Registered
2018-05-24
Start date
2018-08-15
Completion date
2038-04-01
Last updated
2025-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Encephalopathy, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity, Morbid

Brief summary

Prospective non-randomized intervention case control study on patients with a BMI \> 35. The intervention group/cases (n=600) is comprised of bariatric patients who undergo bariatric surgery and the control group (n=600) of age, weight and comorbidity matched patients who choose not to undergo bariatric surgery. The overall aim is to examine prevalence of the spectrum of fatty liver disease (NAFLD) in these patients and the prognostic significance of NAFLD.

Interventions

PROCEDUREBariatric surgery

Roux en y gastric bypass or gastric sleeve operation

Sponsors

University of Southern Denmark
CollaboratorOTHER
Odense University Hospital
CollaboratorOTHER
Esbjerg University Hospital of South-West Jutland
CollaboratorUNKNOWN
Esbjerg Hospital - University Hospital of Southern Denmark
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

case group: * Age \> 18 years * BMI \>35 kg/m2 and referred for bariatric surgery at Hospital of South West Jutland, Denmark * Able to give written informed consent. Inclusion criteria control group: * Age \> 18 years * BMI \>35 kg/m2 with no wish to undergo bariatric surgery. * Able to give written informed consent.

Exclusion criteria

* Active viral hepatitis * Not willing or able to consent * Contraindications to liver biopsy

Design outcomes

Primary

MeasureTime frameDescription
Number of participants who will die during the follow up period in case and control group10 years follow up after inclusionDifference in mortality between cases and controls with various NAFLD severity on biopsy.

Secondary

MeasureTime frameDescription
Number of participant who will experience progressive fatty liver disease in case and control group10 years follow up after inclusionDifference NAFLD severity between case and control group after 10 years follow up. Simple steatosis is the mildest form and liver cirrhosis is the most serious manifestation: 1. Grade 1 steatosis 2. Grade 2 steatosis 3. Grade 3 steatosis 4. Non alcoholic steatohepatitis 5. Presence of fibrosis Kleiner grade 1-2 6. Presence of fibrosis Kleiner grade 3 7. Presence of liver cirrhosis
Change in continuous reaction time measurement after bariatric surgery10 years follow up after inclusionContinuous reaction time measurement will measure reaction time instability and is a measure of metabolic encephalopathy. The method is a 10-minutes, computerised registration of a series of motor reaction times to an auditory stimulus, with results reported as the CRTindex (50 percentile/(90-10) percentile) as a parameter of reaction time variability. A CRT index below 1.9 i considerede abnormal a may be a sign of hepatic encephalopathy.
Change in EEG after bariatric surgery24 months after surgeryChange in mean dominant frequency(MD) on EEG spectral analysis. EEG disturbances in hepatic encephalopathy are (rated by severity)but there is no enough space here to describe it.
Change in intelligence quotient after bariatric surgery24 months efter surgeryMeasured by Weschlers adult intelligence scale (WAIS). An IQ if 100 i the norm. Range 50-150.

Countries

Denmark

Contacts

Primary ContactMette M Lauridsen, MD PhD
mette.enok.munk.lauridsen@rsyd.dk4579182000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026